3G0.F Altimmune Inc

Healthcare Biotechnology Frankfurt Exchange
1.73 EUR
Close of Nov 12, 2026
1.69 5.32
Market cap
EUR 336M
P/E
-
P/B
0.79x
ROE
-19.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 3G0.F undervalued?

Graham number

The Graham number of Altimmune Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Altimmune Inc fundamental analysis

No fundamental analysis for Altimmune Inc yet.

Altimmune Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Altimmune Inc

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Full company profile